Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Amar Dixit

Allergy & Immunology Beaumont, CA Medical Doctor

NPI 1316381650 CMS profile 2790651

81 Highland Springs Ave, Beaumont, CA 92223

Open in the dashboard

General payments

$345,414

708 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amar Dixit of Beaumont, CA is reported in the CMS Open Payments database as having received $345,414 across 708 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $164,963 198
2024 General $89,134 118
2023 General $40,182 77
2022 General $37,023 163
2021 General $12,135 124
2020 General $472 18
2019 General $1,504 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amar Dixit
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Amar Dixit were reported at $164,963. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Amar Dixit Allergy & Immunology median Middle half National median
2019 $1,504 $594 $163–$1,512 $163
2020 $472 $426 $106–$1,233 $114
2021 $12,135 $638 $157–$1,708 $132
2022 $37,023 $790 $205–$1,961 $149
2023 $40,182 $852 $220–$2,147 $160
2024 $89,134 $865 $203–$2,267 $164
2025 $164,963 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genzyme Corporation $125,402 157 payments
  2. BioCryst US Sales Co., LLC $48,163 91 payments
  3. Novartis Pharmaceuticals Corporation $41,783 40 payments
  4. ARS Pharmaceuticals Operations, Inc. $30,737 30 payments
  5. CSL Behring $28,810 63 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $25,338 88 payments
  7. Regeneron Healthcare Solutions, Inc. $23,608 74 payments
  8. Incyte Corporation $13,156 22 payments
  9. AstraZeneca Pharmaceuticals LP $2,142 32 payments
  10. Dermavant Sciences, Inc. $2,009 2 payments
  11. Other $4,267 109 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $181,299 59 payments
  2. Consulting Fee $89,506 28 payments
  3. Travel and Lodging $52,760 158 payments
  4. Food and Beverage $20,737 452 payments
  5. Education $1,087 10 payments
  6. Honoraria $25 1 payment
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $108,921 147 payments
  2. Orladeyo $44,101 90 payments
  3. NEFFY $30,737 30 payments
  4. Andembry $23,709 36 payments
  5. CINRYZE $20,873 33 payments
  6. DUPIXENT Inflammation And Immunology $18,360 64 payments
  7. OPZELURA $13,156 22 payments
  8. DUPIXENT Immunology And Inflammation $2,752 7 payments
  9. EOHILIA $2,228 2 payments
  10. VTAMA $2,009 2 payments
  11. Other $6,414 192 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

708 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record